Theravance Inc., of South San Francisco, said partner Glaxosmithkline plc, of London, reported product sales of Relvar/Breo Ellipta (fluticasone furoate/vilanterol) totaling $18.2 million, and sales of Anoro Ellipta (umeclidinium bromide/vilanterol) totaling $8.2 million.